We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Carmat (ALCAR) EUR0.04

Sell:€22.85 Buy:€22.95 Change: €0.1 (0.43%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:€22.85
Buy:€22.95
Change: €0.1 (0.43%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:€22.85
Buy:€22.95
Change: €0.1 (0.43%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Carmat SAS is a France-based Company engaged in the development and production of heart prosthesis. The Company is developing an orthotopic and biocompatible artificial heart which works like a natural heart and which is hydraulically activated. The Company formed a network of partnerships with hospitals and various scientific companies, such as The Georges Pompidou European Hospital, The Marie Lannelongue Surgical Center, The Hospital Charles Nicolle of Rouen, Dedienne Sante, PaxiTech, Vignal Artru Industries, French Vessels and Blood Institute, Laboratoire de Recherche Biochirurgicale and others. As of December 31, 2011, a company MATRA DEFENSE held a 30.57% stake in the Company’s shareholdings.

Contact details

Address:
36
avenue de l'Europe, Immeuble l'Etendard
VELIZY VILLACOUBLAY
78140
France
Telephone:
+33 (1) 39456450
Website:
www.carmatsa.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ALCAR
ISIN:
FR0010907956
Market cap:
€353.13 million
Shares in issue:
15.38 million
Sector:
Health Care Equipment
Exchange:
Euronext Paris
Country:
France
Currency:
Euro
Indices:
n/a

Key personnel

  • Jean-Pierre Garnier
    Chairman of the Board
  • Stephane Piat
    Chief Executive Officer, Director
  • Pascale d'Arbonneau
    Chief Financial Officer, Head of investor relations
  • Eric Richez
    Sales and Business Development Director
  • Francesco Arecchi
    Marketing Manager
  • Raouia Bouyanzer
    Human Resources Manager
  • Thierry Dupoux
    Quality and Regulatory Affairs Director
  • Alexandre Eleonore
    Manufacturing Director
  • Marc Grimme
    Research and Development Director
  • Petrus Jansen
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.